Inventor
Mark W. Orme
Inventor
Seattle, WA, US
Overview
Patents· 63 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
A61KPreparations for medical, dental or toiletry purposes23%
C07CAcyclic or carbocyclic compounds17%
PatentTitleYear
10,639,286Alkoxy compounds for disease treatment202010,201,545Styrenyl derivative compounds for treating ophthalmic diseases and disorders201910,188,615Alkoxy compounds for disease treatment20199,737,496'Alkoxy compounds for disease treatment'20179,464,033'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20169,458,088'Alkoxy compounds for disease treatment'20169,452,153'Amine derivative compounds for treating ophthalmic diseases and disorders'20169,447,078'Substituted heterocyclic compounds for disease treatment'20169,421,210'Styrenyl derivative compounds for treating ophthalmic diseases and disorders'20169,314,467'Styrenyl derivative compounds for treating ophthalmic diseases and disorders'20169,133,154'Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders'20159,115,056'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20159,079,825'Alkoxy compounds for disease treatment'20159,056,849'Amine derivative compounds for treating ophthalmic diseases and disorders'20158,993,807'Alkoxy compounds for disease treatment'20158,981,153'Alkoxy compounds for disease treatment'20158,895,782'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20148,829,244'Alkoxy compounds for disease treatment'20148,766,007'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20148,716,529'Amine derivative compounds for treating ophthalmic diseases and disorders'20148,653,142'Styrenyl derivative compounds for treating ophthalmic diseases and disorders'20148,492,589'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20138,450,527'Amine derivative compounds for treating ophthalmic diseases and disorders'20138,420,863'Styrenyl derivative compounds for treating ophthalmic diseases and disorders'20138,389,771'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20138,299,307'Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders'20128,076,516'Amine derivative compounds for treating ophthalmic diseases and disorders'20117,982,071'Alkoxy compounds for disease treatment'20117,550,479'Modified Pictet-Spengler reaction and products prepared therefrom'20097,122,554'Carboline derivatives'20067,115,621'Chemical compounds'20067,105,506'Tetracyclic compounds as PDE5-inhibitors'20067,098,209'Pyrazino [1\'2\':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives'20067,034,027'Fused heterocyclic derivatives as phosphodiesterase inhibitors'20067,022,856'Carboline derivatives'20066,992,192'Carboline derivatives as PDE5 inhibitors'20066,984,641'Carboline derivatives as PDE5 inhibitors'20066,962,918'Hexahydropyrazino[1\'2\';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction'20056,960,587'Condensed pyrazindione derivatives as PDE inhibitors'20056,911,542'Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives'20056,903,099'Condensed pyrazindione derivatives'20056,878,711'Indole derivatives as PDE5-inhibitors'20056,872,721'Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1′,2′:1,6]pyrido[3,4b]-indole-1,4-dione'20056,858,620'Condensed pyridoindole derivatives'20056,838,456'Condensed pyridoindole derivatives'20056,825,197'Cyclic GMP-specific phosphodiesterase inhibitors'20046,649,631'Compositions and methods for treating bone deficit conditions'20036,395,740'Calcitonin mimetics'20026,342,514'Compositions and methods for treating bone deficit conditions'20026,251,901'Compositions and methods for treating bone deficit conditions'20016,153,631'Compositions and methods for treating bone deficit conditions'20006,124,299'Calcitonin mimetics'20006,017,940'Compositions and methods for treating bone deficit conditions'20006,008,208'Compositions and methods for treating bone deficit conditions'19995,994,358'Compositions and methods for treating bone deficit conditions'19995,990,169'Compositions and methods for treating bone deficit conditions'19995,965,573'Compositions and methods for treating bone deficit conditions'19995,948,776'Compositions and methods for treating bone deficit conditions'19995,939,444'Compositions and methods for treating bone deficit conditions'19995,922,753'Methods for treating bone deficit conditions with benzothiazole'19995,919,808'Compositions and methods for treating bone deficit conditions'19995,731,326'PDGF antagonists II'19985,401,880'Chemical prevention or reversal of cataract by phase separation inhibitors'1995Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1995–2020Based in Seattle, WA, US· patent location history
1998–2002Patents assigned to ZYMOGENETICS INC (14)· patent assignee history
2004–2009Patents assigned to LILLY ICOS LLC (18)· patent assignee history
2011–2020Patents assigned to ACUCELA INC (28)· patent assignee history
2011–2015Patents assigned to ORME MARK W (13)· patent assignee history
2011–2015Patents assigned to HONG FENG (11)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ACUCELA INC | 28 | 2011–2020 |
| LILLY ICOS LLC | 18 | 2004–2009 |
| ZYMOGENETICS INC | 14 | 1998–2002 |
| ORME MARK Wself | 13 | 2011–2015 |
| HONG FENG | 11 | 2011–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Seattle, Washington, US | 63 | 1995–2020 |